Past-President of the Metastasis Research Society (MRS), Dr. Patricia Steeg of the NCI, has been appointed to an Implementation Committee of the Beau Biden Cancer Moonshot in the U.S. The goal of the Moonshot effort is to make a decade’s worth of progress in cancer research in just 5 years. The initiative is a collaborative effort between researchers, clinicians, and patient advocates.
At the end of 2016, the Blue Ribbon Panel (BRP) of the Cancer Moonshot published a report outlining scientific priorities or recommendations for accelerating cancer research and improving treatment. Of interest to metastasis researchers in particular are the portions of the report pertaining to “Tumor Evolution and Progression” and “Cancer Immunology.”
Right now there are six areas of funding that are currently open for applications based upon existing NCI funding goals and the BRP recommendations. The grant priorities are intended to speed up delivery of effective therapeutics, not new initiatives.
The six current funding areas include: 1) Gene Fusions in Pediatric Sarcomas, 2) Emerging Questions in Cancer Systems Biology, 3) Preclinical Model Development to Support Drug Development and Discovery, 4) Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research, 5) Metabolic Reprogramming to Improve Immunotherapy, and 6) Collaborative Research Projects to Enhance Applicability of Mammalian Models for Translational Research.